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Abstract. Lenvatinib is an oral, multitargeted tyrosine kinase 
inhibitor (TKI) of VEGFR1-VEGFR3, FGFR1-FGFR4, 
PDGFRα, RET and v-kit Hardy-Zuckerman 4 feline sarcoma 
viral oncogene homolog (KIT) signaling networks involved in 
tumor angiogenesis. We have evaluated the antitumor activity 
of lenvatinib in primary anaplastic thyroid cancer (ATC) cells, 
in the human cell line 8305C (undifferentiated thyroid cancer) 
and in an ATC-cell line (AF). The AF cell line was obtained 
from the primary ATC cultures and was the one that grew over 
50 passages. The effect of lenvatinib (1 and 100 nM; and 1, 10, 
25 and 50 µM) was investigated in primary ATC, 8305C and 
AF cells as well as in AF cells in CD nu/nu mice. Lenvatinib 
significantly reduced ATC cell proliferation (P<0.01, ANOVA) 
and increased the percentage of apoptotic ATC cells (P<0.001, 
ANOVA). Furthermore, lenvatinib inhibited migration 
(P<0.01) and invasion (P<0.001) in ATC. In addition, lenva-
tinib inhibited EGFR, AKT and ERK1/2 phosphorylation 
and downregulated cyclin D1 in the ATC cells. Lenvatinib 
also significantly inhibited 8305C and AF cell proliferation, 
increasing apoptosis. AF cells were subcutaneously injected 
into CD nu/nu mice and tumor masses were observed 20 days 
later. Tumor growth was significantly inhibited by lenva-
tinib (25 mg/kg/day), as well as the expression of VEGF-A and 
microvessel density in the AF tumor tissues. In conclusion, the 
antitumor and antiangiogenic activities of lenvatinib may be 
promising for the treatment of anaplastic thyroid cancer, and 
may consist a basis for future clinical therapeutic applications.
Introduction
Lenvatinib is an oral, multitargeted tyrosine kinase 
inhibitor (TKI) of vascular endothelial growth factor recep-
tors 1-3 (VEGFR1-VEGFR3), fibroblast growth factor 
receptors 1-4 (FGFR1-FGFR4), PDGFRα, RET and v-kit 
Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 
(KIT) signaling networks involved in tumor angiogenesis (1).
In vitro studies have evaluated lenvatinib in preclinical 
models. Lenvatinib decreased the auto-phosphorylation of 
KIF5B-RET, CCDC6-RET and NcoA4-RET, inhibited the 
proliferation of CCDC6-RET human thyroid and lung cancer 
cell lines and blocked the tumorigenicity of RET gene fusion-
transformed NIH3T3 cells (2). Orally administered lenvatinib 
exhibited antitumor activity in xenograft models of five differ-
entiated thyroid cancer (DTC) cell lines, five anaplastic thyroid 
cancer (ATC) cell lines and one medullary thyroid cancer 
cell line (3). Lenvatinib exhibited antiangiogenic activity in 
five DTC and five ATC xenografts, while its antiproliferative 
activity was shown in vitro only in 2/11 thyroid cancer cell 
lines (i.e. RO82-W-1 and TT cells). Lenvatinib was also able 
to inhibit RET phosphorylation in TT cells with the activating 
mutation C634W (3).
In vivo phase II (4,5) and phase III (6) studies in patients 
with aggressive DTC not responsive to radioiodine have 
demonstrated that the administration of lenvatinib is associated 
with an improvement in progression-free survival (PFS) 
compared with placebo (median PFS 18.2 vs. 3.6 months). 
Following the results of this phase III study, lenvatinib has been 
approved for the treatment of patients with locally recurrent or 
metastatic, progressive, radioactive iodine refractory DTC (7).
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ATC is one of the most aggressive human types of tumor. 
Lymph node or distant metastases are present in ~80% of 
patients at diagnosis (8-10) and the median survival rate is 
6 months (11,12). Multimodal treatment, including debulking, 
hyperfractionated accelerated external beam radiotherapy and 
chemotherapy (doxorubicin, paclitaxel, docetaxel and cisplatin) 
is the most effective treatment strategy, and improves median 
survival rate to ~10 months (13,14).
Several genetic alterations have been identified in ATC 
molecular pathways, involving p53, BRAF, RAS, RET/PTC, 
VEGFR1, VEGFR2, EGFR, PDGFRα, PDGFRβ, KIT, MET, 
PIK3Ca, PIK3Cb and PDK1, that lead to tumor aggressiveness 
and progression (14,15). New drugs targeting these molecular 
alterations have been recently evaluated in ATC (14).
Recent anecdotal evidence and a phase II clinical study 
have reported the antineoplastic activity of lenvatinib in 
ATC (16-20). In the present study, we aimed to evaluate the 
antineoplastic activity of lenvatinib in ATC continuous cell 
lines and in primary ATC cell cultures both in vitro and in vivo.
Materials and methods
Chemicals and supplements. Lenvatinib (1 and 100 nM; and 
1, 10, 25 and 50 µM) was evaluated in primary ATC cell 
cultures, in 8305C cells (DSMZ, Braunschweig, Germany) 
and AF cells, and in AF cells in CD nu/nu mice. Chemicals 
and supplements were obtained from Sigma-Aldrich 
(Merck KGaA, Darmstadt, Germany). RPMI-1640 medium 
was purchased from Gibco (Thermo Fisher Scientific, Inc., 
Waltham, MA, uSA). PCR reagents for quantitative PCR 
were purchased from Applied Biosystems (Thermo Fisher 
Scientific, Inc.).
Thyroid tissues. Thyroid samples were surgically collected 
from 9 ATC patients and from 5 healthy subjects undergoing 
parathyroidectomy. The diagnosis was made on the basis 
of clinical and histological criteria by a recognized labora-
tory (21-23). By immunohistochemistry it was demonstrated 
that TSH receptor, sodium/iodide symporter (NIS), thyroper-
oxidase (TPO) and thyroglobulin (Tg) were not expressed in 
thyroid tissues.
DNA extraction and microdissection and detection of 
BRAF mutation were conducted through PCR single strand 
conformation polymorphism assays, using accepted protocols 
such as direct DNA sequencing (21-23). All patients agreed to 
take part in the study and provided written informed consent. 
The study was authorized by the local Ethics Committee of the 
university of Pisa.
Cell cultures
Human primary ATC cell cultures. ATC cell cultures were 
established as previously described (21-23). Tumor samples 
were divided into pieces of 1-3 mm with a lancet or clippers. 
The obtained fragments were washed 3-5 times in M-199 
media containing penicillin (500,000 u/l), streptomycin 
(500,000 u/l) and nystatin (1,000,000 u/l). Then, neoplastic 
samples were suspended in Dulbecco's modified Eagle's 
medium (DMEM) with penicillin/streptomycin (50 mg/l), 
glutamine (1% w/v) and fetal calf serum (FCS) (20% v/v), at 
37̊C and 5% CO2.
As primary cultures reached confluence, the cells were 
separated with a trypsin solution, then moved into flasks for 
the primary tissue cultures (Becton-Dickinson Labware, 
Bedford, MA, uSA). After reaching the third passage, the cells 
were coated with methocel (24) for the evaluation of colony-
forming efficiency. Subsequently, the biggest colonies were 
isolated and amplified in flasks for tissue cultures (21-23) and 
the required tests were performed at the fourth passage.
The absence of expression of the TSH receptor (25), Tg, 
NIS (26) and TPO (27) was investigated by immunocyto-
chemistry, as was the presence of cytokeratin (26), which 
exhibited a partial and focal positivity. A pattern similar to 
that of the original neoplastic tissue was reported by DNA 
fingerprinting (21-23).
Thyroid follicular cell (TFC) culture. Primary TFC 
cultures were established as previously described (28). 
The specimens were minced and digested with collagenase 
(1 mg/ml; Roche Diagnostics, Almere, The Netherlands) 
in RPMI-1640 (Whittaker Bioproducts, Inc., Walkersville, 
MD, USA) for 1 h at 37̊C. Semi-digested follicles were 
removed, sedimented for 2 min, washed and cultured in 
RPMI-1640 with 10% fetal bovine serum (FBS; Seromed, 
Biochrom, Germany), 2 mM glutamine and 50 mg/ml peni-
cillin/streptomycin at 37̊C and 5% CO2 in plastic 75-cm2 
flasks (Sarstedt, Verona, Italy).
AF cell line. Nine primary ATC cell cultures were established 
and among them the AF cell line grew in nu/nu mice, after 
being subcutaneously inoculated.
8305C cell line. As the control, 8305C cells, an undifferen-
tiated thyroid cancer continuous cell line (DSMZ), with a 
papillary component, were seeded in RPMI-1640 with 15% 
FBS and 2 mM L-glutamine.
Evaluation of cell viability and proliferation. In order to inves-
tigate cell proliferation, we conducted an MTT assay, using 
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide 
(WST-1; Roche Diagnostics) (22,23,28). The 8305C, AF, ATC 
and TFC cell lines were plated (35,000 cells/ml) at 100 µl/well 
and treated for 24 h with lenvatinib at different concentra-
tions or the vehicle alone (four wells for each concentration). 
The IC50 value was determined with linear interpolation. 
Triplicate experiments were conducted for each cell prepara-
tion (22,23,28). The absorbance at 450 nm was estimated at 
1 and 2 h from the beginning of the tetrazolium reaction.
Furthermore, to assess the proliferation rate of the TFC, 
ATC, AF and 8305C cell lines, cell number counting was also 
performed (22,23,28).
Apoptosis: Hoechst uptake and Annexin V binding assay. The 
8305C, AF and ATC cells were plated in wells (35,000 cells/ml, 
in 100 µl/well) and treated for 48 h with lenvatinib in a humidi-
fied atmosphere (37̊C, 5% CO2). The cells were then dyed 
with Hoechst 33342 (28). Subsequently, the apoptosis index 
(apoptotic cells/total cells x 100) was determined. The apop-
tosis evaluation was conducted using the Annexin V binding 
method. The cells were plated in the Lab-Tek II Chamber 
Slide system (Nalge Nunc International, Penfield, NY, USA) 
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and treated with lenvatinib for 48 h. The apoptosis index was 
calculated as previously reported (28).
Migration and invasion tests. Migration and invasion assays 
were performed using Transwell permeable supports (Corning 
Life Sciences, Corning, NY, uSA) (29,30). Cell cultures were 
starved for 5 h in serum-free medium at 37̊C, 5% CO2, then 
collected with a solution of PBS and 5 mM EDTA. Total cell 
number was calculated. After centrifugation, the cells were 
seeded at a concentration of 0.5x105 cells/well in serum-free 
medium.
To produce a gradient, 10% v/v FCS (or serum-free 
medium as negative control) was added to receiver wells with 
increasing concentrations of lenvatinib and then, the medium 
was removed from the lower compartments, and calcein AM 
(2 µg/ml; Sigma-Aldrich) was added for 1 h. An ELISA reader, 
with filters set to 485 nm for excitation and 520 nm for emis-
sion, was used to assess the intracellular fluorescence.
For the migration assay, cells were incubated for 12 h and 
for the invasion assay, cells were incubated for 24 h. A base-
ment membrane extract (Trevigen, Gaithersburg, MD, uSA) 
was used overnight (37̊C, 5% CO2) for invasion. To obtain 
the number of migrated or invasive cells with respect to the 
fluorescence values, a standard curve with various cell concen-
trations was generated.
ELISA tests in ATC cells
Phospho-EGFR inhibition cell-based assay. ATC cells 
were plated (5x104 cells/well) in 1% FBS medium and 
treated for 72 h (after 24 h of incubation) with lenvatinib at a 
concentration close to the experimental IC50 of the cell prolif-
eration test (25 µM for ATC), or with a higherx (50 µM), or 
lower (1 µM) concentration or with vehicle. Cell lysates were 
then harvested (31) and evaluated using PathScan phospo-
EGFR (Tyr1173) and total EGFR ELISA kits (Cell Signaling 
Technology, Inc., Danvers, MA, uSA). Optical density (OD) 
was assessed at 450 nm.
ERK1/2 (pTpY185/187) and Akt (pThr308) ELISA. ATC cells 
were plated (5x104 cells/well) and treated with lenvatinib for 
72 h (31). Then, cell lysates were evaluated for human ERK1/2 
and Akt phosphorylation using PhosphoDetect ERK1/2 
(pThr185/pTyr187) and the PhosphoDetect Akt (pThr308) ELISA 
kits (Calbiochem; EMD Millipore, Billerica, MA, uSA). To 
normalize the obtained data, total protein ERK1/2 and Akt 
concentrations were determined with ERK1/2 and Akt ELISA 
kits, respectively. OD was estimated at 450 nm.
Cyclin D1 protein expression is quantified in lenvatinib-
treated ATC cells. To evaluate the effect of lenvatinib on protein 
cyclin D1 modulation, ATC cells were treated with lenvatinib 
for 72 h (at the previously indicated concentrations) or with 
vehicle alone (31). The amount of cyclin D1 was quantified in 
cell lysates, obtained using lysis buffer (ice-cold 1X; 0.5 ml), 
with sonication on ice for 10 sec. After microcentrifugation 
for 10 min at 4̊C, supernatants were collected and assessed 
using a human cyclin D1 ELISA kit (uSCN Life Science and 
Technology Co., Wuhan, China). OD was assessed at 450 nm 
and the obtained data were reported as cyclin D1 ng/mg of 
total protein.
In vivo studies
Animals and treatment. Six-week-old CD nu/nu male mice, 
provided by Envigo (Milan, Italy), were housed in microiso-
lator cages on vented racks and manipulated using aseptic 
techniques. Housing and procedures involving animals were 
conducted according to the protocol approved by the Academic 
Organization Responsible for Animal Welfare [Organismo 
Preposto per il Benessere Animale (OPBA)] at the university 
of Pisa, according to the Italian law D.lgs. 26/2014, and with 
the approval of the Italian ministry of Health (authorization 
no. 613/2015-PR).
Each experiment employed the minimum number of mice 
needed to obtain statistically meaningful results. On day 0, 
4x106±5% viable AF cells/mouse were subcutaneously inocu-
lated. Animal weights were monitored and tumor volume 
(mm3) was defined as: [(w1 x w1 x w2) x (π/6)], where w1 and w2 
were the smallest and the largest tumor diameter (mm), respec-
tively. Treatment (n=6 mice/group) was initiated 20 days after 
cell inoculation, when the mean volume was ~100 mm3. All 
mice were randomized shortly before the initiation of treat-
ment. Control mice received vehicle alone. Lenvatinib was 
administered at 25 mg/kg by gavage daily without interruption 
for 16 days. Mice were sacrificed using an anesthetic overdose, 
after which tumors were excised and measured.
Tumor tissue: Immunohistochemistry and microvessel density 
determination. Neoplastic samples from the two treatment 
groups were weighed, then fixed in formalin and subsequently 
embedded in paraffin. Sections of 5-µm thickness were stained 
by hematoxylin and eosin (H&E), as previously described (29).
VEGF expression was evaluated with an anti-VEGF rabbit 
polyclonal antibody (cat. no. sc-152; Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA, uSA) at 1:50 dilution. Expression was 
presented as a percentage of positive cells out of at least 
1,000 tumor cells. Microvascular count (MVC) was evalu-
ated using anti-FVIII polyclonal antibody (cat. no. 760-2642; 
Ventana Medical Systems) as previously reported (29).
Statistical analysis. Data are presented as the mean (± SD) 
for normally distributed variables, or as the median and 
interquartile range. Experiments were conducted in triplicate 
from each subject and the mean of the samples was reported 
for TFC and ATC cells. One-way ANOVA, Mann-Whitney u 
or Kruskal-Wallis test were used to compare mean group 
values for normally distributed variables. The χ2 test was 
used to compare group proportions. Post hoc comparisons 
on normally distributed variables were performed using 
the Bonferroni-Dunn test. Analysis of apoptosis results was 
performed using one-way ANOVA with the Newman-Keuls 
multiple comparison test.
Results
In vitro studies in ATC cells
Evaluation of cell proliferation. Data obtained from the 
WST-1 test in ATC cells demonstrated a significant reduction 
in cell proliferation rate vs. the control group with lenvatinib 
at 1 h from the beginning of the tetrazolium reaction. Cell 
counting confirmed these results. After 1 h, the cell number 
was 11,850±620/100 µl/well in the ATC control group; 
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11,613±680 (98%) with lenvatinib 1 nM; 11,496±890 (97%) with 
lenvatinib 100 nM; 11,376±790 (96%) with lenvatinib 1 µM; 
9,480±600 (80%) with lenvatinib 10 µM; 7,229±460 (61%) 
with lenvatinib 25 µM; and 4,503±450 (38%) with lenvatinib 
50 µM (P<0.01, ANOVA). The WST-1 assay in ATC cells also 
demonstrated a significant reduction in the proliferation rate vs. 
the control group with lenvatinib at 2 h from the beginning of 
the tetrazolium reaction (P<0.01, for both, ANOVA) (Fig. 1A). 
Cell counting confirmed these results; after 2 h, the cell 
number was 18,720±820/100 µl/well in the ATC control group; 
18,532±780 (99%) with lenvatinib 1 nM; 17,784±990 (95%) 
with lenvatinib 100 nM; 18,158±810 (97%) with lenvatinib 
1 µM; 11,232±1,100 (60%) with lenvatinib 10 µM; 8,425±960 
(45%) with lenvatinib 25 µM; and 2,995±750 (16%) with lenva-
tinib 50 µM; (P<0.01, ANOVA). The IC50 value for lenvatinib, 
obtained by linear interpolation, was 19±2.5 µM.
Data obtained from the WST-1 assay in TFC cells following 
lenvatinib treatment demonstrated a slight but significant 
reduction in the proliferation rate vs. the control group both 
at 1 h (P<0.01, ANOVA) with lenvatinib 10 µM (96% vs. 
control), 25 µM (90% vs. control) and 50 µM (85% vs. control) 
and at 2 h (P<0.01, ANOVA) with lenvatinib 10 µM (90% 
vs. control), 25 µM (85% vs. control) and 50 µM (81% vs. 
control). Cell counting confirmed these results: after 1 h, the 
cell number was 10,150±620/100 µl/well in the TFC control; 
9,642±1,100 (95%) with lenvatinib 10 µM; 9,238±960 (91%) 
with lenvatinib 25 µM; and 8,625±950 (85%) with lenvatinib 
50 µM; (P<0.01, ANOVA); after 2 h, the cell number was 
17,500±820/100 µl/well; 15,925±1,120 (91%) with lenvatinib 
10 µM; 14,874±1,060 (85%) with lenvatinib 25 µM; and 
14,350±980 (82%) with lenvatinib 50 µM (P<0.01, ANOVA).
Proliferation and BRAF. The V600EBRAF mutation was 
detected in three ATC samples. RET/PTC1 and RET/PTC3, 
N-RAS or H-RAS mutations evaluated by quantitative PCR 
were not detected in primary ATC cell cultures. Proliferation 
was inhibited in a similar manner in ATC from tumors in the 
presence/absence of V600EBRAF mutation (data not shown).
Apoptosis evaluation. Lenvatinib dose-dependently increased 
apoptotic ATC cells (P<0.001, ANOVA; Fig. 1B). The 
Annexin V assay corroborated these results (Fig. 1C and D).
Migration and invasion tests. After reaching subconfluence, 
primary ATC cell cultures were treated with increasing 
concentrations of lenvatinib. Lenvatinib inhibited migra-
tion (Fig. 2A) and invasion (Fig. 2B), as evaluated by the 
Transwell chamber (Corning Life Sciences).
Figure 1. Proliferation (WST-1) and apoptosis assays in primary human ATC. (A) WST-1 assay in primary ATC cell cultures treated with lenvatinib for 24 h. 
Lenvatinib significantly reduced the proliferation of ATC cells vs. the control. Bars represent the mean (± SD). *P<0.05 vs. control with Bonferroni-Dunn 
test. (B) ATC cell apoptosis after treatment with lenvatinib for 48 h. Apoptosis was strongly and dose-dependently increased by lenvatinib. Apoptosis was 
evaluated by Hoechst staining. Data are expressed as the mean (± SD) (n=9), and analyzed by one-way ANOVA with Newman-Keuls multiple comparison test, 
and with a linear trend test (P<0.001 vs. control). (C and D) Representative example of the Annexin V binding assay in control ATC and treated cells (with 
lenvatinib 50 µM), respectively. ATC, anaplastic thyroid cancer.
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Inhibition of EGFR. Lenvatinib significantly and dose-depend-
ently decreased the phosphorylated form of EGFR in ATC cell 
lysates (Fig. 3A).
Inhibition of Akt or ERK1/2 phosphorylation. Phosphorylated/
non-phosphorylated Akt or ERK1/2 proteins (evaluated by 
ELISA) in lenvatinib-treated samples were significantly 
reduced in ATC cell cultures (Fig. 3B and C).
Lenvatinib reduces cyclin D1 protein levels. Lenvatinib dose-
dependently inhibited cyclin D1 gene expression in ATC cell 
cultures (Fig. 3D; P<0.05). The intracellular cyclin D1 protein 
Figure 2. Migration and invasion assays in ATC cells. ATC cells were incubated with lenvatinib for (A) 12 h for the migration assay and for (B) 24 h for the 
invasion assay. For comparison, the inhibition of proliferation (at 12 h) (% with respect to control) and the inhibition of migration are reported in the table below 
Fig. 2A, as well as the inhibition of proliferation (at 24 h) (% with respect to control) and the inhibition of invasion in the table below Fig. 2B. Bars represent 
the mean (± SD); *P<0.05 vs. control (control, medium + FCS 10%) by Newman-Keuls test. ATC, anaplastic thyroid cancer.
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was evaluated in cells exposed to lenvatinib or to vehicle. 
Lenvatinib reduced cyclin D1 concentrations compared with 
vehicle-treated cells.
In vitro studies in 8305C and AF cells. Lenvatinib had a 
dose-dependent antiproliferative activity in 8305C cells 
(IC50 of 6.3±2.2 µM) (Fig. 4A) and in AF cells (IC50 of 
8.2±3.1 µM) (Fig. 4B). Furthermore, lenvatinib increased 
apoptotic 8305C cells in a dose-dependent manner. Following 
exposure to lenvatinib 10 µM, 15% of cells were apoptotic 
and with lenvatinib 25 or 50 µM, 23.3 and 29.8% of cells 
were apoptotic, respectively (Fig. 4C; P<0.001, by ANOVA). 
Apoptotic AF cells also increased in a dose-dependent manner. 
Following exposure to lenvatinib 10 µM, 19.8% of cells were 
apoptotic and with lenvatinib 25 or 50 µM, 25 and 30.8% 
of cells were apoptotic, respectively (Fig. 4D; P<0.001, by 
ANOVA).
In vivo studies
Lenvatinib reduces AF tumor growth with no weight loss. 
Twenty days after the subcutaneous xenotransplantation of 
AF cells in CD nu/nu mice, tumor masses reached an average 
volume of 100 mm3 and the treatment started. Lenvatinib 
(25 mg/kg/day i.p.) significantly reduced tumor growth, 
from day 7 after treatment started, compared with the 
controls (Fig. 5A; e.g., at day 7, 107.3 mm3 vs. 408.1 mm3 in 
controls and at day 16, 119.3 mm3 vs. 1016.1 mm3 in controls; 
P<0.05). Notably, no loss of weight was observed throughout 
the course of the experiment indicating that lenvatinib treat-
ment was well tolerated (Fig. 5B).
Lenvatinib reduces VEGF-A expression and microvessel 
density in AF tumor tissues. Inoculation of AF cells led to the 
formation of a tumor that was histologically consistent with 
ATC. Lenvatinib significantly reduced VEGF-A and FVIII 
immunostaining. A localized immunoreactivity for VEGF-A 
Figure 3. Inhibition of EGFR, Akt and ERK1/2 phosphorylation and cyclin D1 protein expression in ATC cells. (A) Inhibition of EGFR phosphorylation 
by lenvatinib in ATC cells after 72 h of treatment. Experiments were performed in triplicate, independently, with at least 9 samples for each dose. Data are 
presented as the mean values (± SE); *P<0.05 vs. control (treated with vehicle). (B and C) Inhibition of ERK1/2 (pThr185/pTyr187) and Akt (pThr308) phosphoryla-
tion by lenvatinib in ATC cells after 72 h of treatment. Experiments were performed in triplicate, independently, with at least 9 samples for each dose. Data 
are presented as the mean values (± SE); *P<0.05 vs. control (treated with vehicle). (D) Cyclin D1 protein concentrations in ATC cells treated with lenvatinib 
or with vehicle alone for 72 h, quantified by ELISA. Cyclin D1 values were reported as ng/mg of total protein. Experiments were performed, independently, 
6 times with at least 9 samples for each dose. Data are presented as the mean values (± SE); *P<0.05 vs. control (treated with vehicle).
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was identified in cells of the control cancer mass which was 
reduced by lenvatinib (48±8 vs. 35±6; P<0.05), with a simul-
taneous reduction of microvessel density (14±5 vs. controls 
23±6; P<0.05).
Figure 4. WST-1 and apoptosis assays in 8305C and AF cells. (A) WST-1 in 8305C or (B) AF cells treated with lenvatinib for 24 h. Lenvatinib significantly 
reduced the proliferation of ATC cells vs. the control. Bars represent the mean (± SD); *P<0.05 vs. control by Bonferroni-Dunn test. Apoptosis in (C) 8305C 
or (D) AF cells treated with lenvatinib for 48 h. Lenvatinib strongly and dose-dependently increased apoptosis (apoptosis was evaluated by Hoechst staining). 
One-way ANOVA was used to analyze the data (with Newman-Keuls multiple comparison test and with a test for linear trend). Data are presented as the mean 
values (± SE) P<0.001 vs. control. IC50 vs. control was evaluated by nonlinear regression (see Results); IC50 was 6.3±2.2 µM for 8305C cells and 8.2±3.1 µM 
for AF cells. ATC, anaplastic thyroid cancer.
Figure 5. In vivo experiments. (A) Antitumor in vivo effect of lenvatinib at the dose of 25 mg/kg/day by gavage, on AF tumors xenotransplanted in CD nu/nu 
mice. (B) Weights of mice monitored during the treatment with lenvatinib or vehicle alone. Symbols and bars, mean (± SE); *P<0.05 vs. vehicle-treated controls.
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Discussion
Research on the effects of TKIs for the treatment of ATC is 
ongoing (32). In the present study, we demonstrated that lenva-
tinib inhibited primary ATC cell cultures proliferation in vitro, 
while also increasing apoptosis and inhibiting migration and 
invasion. In addition, lenvatinib inhibited the proliferation 
of 8305C and AF cells in vitro, while also increasing apop-
tosis and reduced AF cell tumor growth in CD nu/nu mice 
with no toxicity. These results were consistent with previous 
studies that identified an ability of lenvatinib to inhibit tumor 
growth of ATC cell lines in vivo and to disrupt angiogenesis 
by decreasing vascular permeability. An important antiangio-
genic activity of lenvatinib in 8305C xenotransplants has also 
been reported (2,3). In the present study, the antiproliferative 
effect of lenvatinib in primary ATC cells was observed in all 
the samples, independently from the absence or presence of 
V600EBRAF mutation. This is probably due to lenvatinib being 
a multiple signal transduction inhibitor with antiangiogenic 
effect.
The pharmacological and molecular inhibition of PI3K 
or AKT isoforms can reduce in vitro growth and motility in 
human TC cell lines (33,34). RAS-RAF-MAPK, ERK and 
PI3K pathways are implicated in the carcinogenesis of TCs and 
mutations in these genes are present in ATC (35). In ATC, ERK 
and AKT proteins were phosphorylated and activated and were 
thus considered as possible therapeutic targets. In the present 
study, we demonstrated that lenvatinib inhibited ERK1/2 and 
AKT phosphorylation in ATC cells. In addition, lenvatinib 
was demonstrated to reduce EGFR phosphorylation, which is 
consistent with the data reported by Di Desidero et al (36) and 
with our previous results on EGFR phosphorylation inhibition 
by CLM3 in ATC cells (37).
A previous study has indicated the important role of 
cyclin D1 in the regulation of cell cycle progression (38). 
Cyclin D1 expression was identified by Lee et al (39) in 67% of 
ATCs and by Wiseman et al (40) in 77% of ATCs. Lenvatinib 
is a dual TKI, acting on EGFR and VEGFR-2, and is able 
to inhibit cell growth by downregulating the expression of 
cyclin D1 and E (41). In the present study we demonstrated 
that lenvatinib potentially downregulates cyclin D1 protein in 
the ATC cells.
Lenvatinib exhibited a low-toxicity profile, since it signifi-
cantly inhibited AF cell growth in CD nu/nu mice with no 
weight loss, unlike other compounds that cause various 
side-effects in humans and animals (42). However, further 
studies are required in order to elucidate potential side-
effects on the function of the kidney, liver and other systems. 
Nevertheless, it may be hypothesized that the antineoplastic 
activity of lenvatinib in ATC is the result of multiple effects 
on tumor cells, namely: i) an antiproliferative activity; 
ii) increased apoptosis; iii) inhibition of migration and inva-
sion; and iv) inhibition of cancer neovascularization.
Currently, novel therapeutic options for ATC are being 
developed, although some limitations still exist in the selec-
tive use of new molecules. For example, even if there are 
potential targets in the tumor tissue, such as BRAF, tumor 
response may only occur in a fraction of patients, and this 
could be due to the activation of compensatory signal path-
ways, allowing cancer cell proliferation. The effectiveness 
of the treatments could be increased by testing the sensi-
tivity of primary ATC cells from each subject to different 
TKIs, as in vitro chemosensitivity tests can predict in vivo 
effectiveness in 60% of cases (43). In addition, a negative 
chemosensitivity test in vitro is associated with a 90% chance 
of ineffectiveness in vivo (43,44). This is important in order 
to avoid the administration of inactive chemotherapeutics to 
patients (21,22,30,32).
In the present study, we revealed for the first time the anti-
tumoral effect of lenvatinib, a multi-targeted kinase inhibitor, 
in primary human ATC cell cultures obtained from patients. 
These findings could open the way to the clinical use of lenva-
tinib in the treatment of patients with ATC.
Acknowledgements
Not applicable.
Funding
GB was supported by a grant from the Associazione Italiana 
per la Ricerca sul Cancro (IG-17672).
Availability of data and materials
All data generated or analyzed during this study are included 
in this published article.
Authors' contributions
SMF, GB, PM, AA and PF made substantial contributions to 
conception and design, and to acquisition of data; TDD, GE, 
IR, FR, PO, SRP, AP, SP, CLM, Su, EB and GM analyzed 
the data; SMF, GB, TDD, AA and PF have been involved in 
drafting the manuscript; AA revised it critically for important 
intellectual content. All authors read and approved the final 
manuscript.
Ethics approval and consent to participate
All patients and controls agreed to enter the study, which was 
approved by the local Ethics Committee of the university of 
Pisa (see Materials and methods).
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
References
 1. Costa R, Carneiro BA, Chandra S, Pai SG, Chae YK, Kaplan JB, 
Garrett HB, Agulnik M, Kopp PA and Giles FJ: Spotlight on 
lenvatinib in the treatment of thyroid cancer: Patient selection 
and perspectives. Drug Des Devel Ther 10: 873-884, 2016.
 2. Okamoto K, Kodama K, Takase K, Sugi NH, Yamamoto Y, 
Iwata M and Tsuruoka A: Antitumor activities of the targeted 
multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET 
gene fusion-driven tumor models. Cancer Lett 340: 97-103, 2013.
ONCOLOGY REPORTS  39:  2225-2234,  2018 2233
 3. Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, 
Okamoto K, Minoshima Y, Iwata M and Funahashi Y: 
Antitumor activity of lenvatinib (e7080): An angiogenesis 
inhibitor that targets multiple receptor tyrosine kinases in 
preclinical human thyroid cancer models. J Thyroid Res 2014: 
638747, 2014.
 4. Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, 
Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner DL, 
Topliss D, et al: A phase 2 trial of lenvatinib (E7080) in 
advanced, progressive, radioiodine-refractory, differentiated 
thyroid cancer: A clinical outcomes and biomarker assessment. 
Cancer 121: 2749-2756, 2015.
 5. Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, 
Ball DW, McCaffrey J, Newbold K, Allison R, Martins RG, et al: 
A phase II trial of the multitargeted tyrosine kinase inhibitor 
lenvatinib (E7080) in advanced medullary thyroid cancer. Clin 
Cancer Res 22: 44-53, 2016.
 6. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, 
Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, et al: 
Lenvatinib versus placebo in radioiodine-refractory thyroid 
cancer. N Engl J Med 372: 621-630, 2015.
 7. Nair A, Lemery SJ, Yang J, Marathe A, Zhao L, Zhao H, Jiang X, 
He K, Ladouceur G, Mitra AK, et al: FDA approval summary: 
Lenvatinib for progressive, radio-iodine-refractory differentiated 
thyroid cancer. Clin Cancer Res 21: 5205-5208, 2015.
 8. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, 
Haller DG and Morrow M: Thyroid. In: AJCC Cancer Staging 
Manual. 6th edition. Springer-Verlag, New York, p77, 2002.
 9. Miccoli P, Materazzi G, Antonelli A, Panicucci E, Frustaci G 
and Berti P: New trends in the treatment of undifferentiated 
carcinomas of the thyroid. Langenbecks Arch Surg 392: 397-404, 
2007.
10. Kebebew E: Anaplastic thyroid cancer: Rare, fatal, and neglected. 
Surgery 152: 1088-1089, 2012.
11. Hundahl SA, Fleming ID, Fremgen AM and Menck HR: A 
National Cancer Data Base report on 53,856 cases of thyroid 
carcinoma treated in the u.S., 1985-1995 [see commetns]. 
Cancer 83: 2638-2648, 1998.
12. Kitamura Y, Shimizu K, Nagahama M, Sugino K, Ozaki O, 
Mimura T, Ito K, Ito K and Tanaka S: Immediate causes of death 
in thyroid carcinoma: Clinicopathological analysis of 161 fatal 
cases. J Clin Endocrinol Metab 84: 4043-4049, 1999.
13. De Crevoisier R, Baudin E, Bachelot A, Leboulleux S, 
Travagli JP, Caillou B and Schlumberger M: Combined treatment 
of anaplastic thyroid carcinoma with surgery, chemotherapy, and 
hyperfractionated accelerated external radiotherapy. Int J Radiat 
Oncol Biol Phys 60: 1137-1143, 2004.
14. Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, 
Burman KD, Kebebew E, Lee NY, Nikiforov YE, Rosenthal MS, 
et al; American Thyroid Association Anaplastic Thyroid Cancer 
Guidelines Taskforce: American Thyroid Association guidelines 
for management of patients with anaplastic thyroid cancer. 
Thyroid 22: 1104-1139, 2012.
15. Antonelli A, Fallahi P, Ferrari SM, Ruffilli I, Santini F, 
Minuto M, Galleri D and Miccoli P: New targeted therapies for 
thyroid cancer. Curr Genomics 12: 626-631, 2011.
16. Yamazaki H, Shimizu S, Iwasaki H, Yoshida T, Suganuma N, 
Yamanaka T, Kojima I, Masudo K, Toda S, Nakayama H, et al: 
Efficacy and safety of lenvatinib for unresectable anaplastic 
thyroid cancer. Gan To Kagaku Ryoho 44: 695-697, 2017 
(In Japanese).
17. Iñiguez-Ariza NM, Ryder MM, Hilger CR and Bible KC: Salvage 
lenvatinib therapy in metastatic anaplastic thyroid cancer. 
Thyroid 27: 923-927, 2017.
18. Oishi K, Takabatake D and Shibuya Y: Efficacy of lenvatinib 
in a patient with anaplastic thyroid cancer. Endocrinol Diabetes 
Metab Case Rep 2017. pii: 16-0136, 2017. https://doi.org/10.1530/
EDM-16-0136.
19. Fukuhara T, Donishi R, Koyama S, Miyake N, Matsuda E, 
Fujiwara K, Kitano H and Takeuchi H: Significant amelioration 
of tracheal stenosis following lenvatinib in a patient who has 
anaplastic thyroid carcinoma with bronchomediastinal infil-
tration: A Case Report. Case Rep Oncol 10: 175-181, 2017.
20. Tahara M, Kiyota N, Yamazaki T, Chayahara N, Nakano K, 
Inagaki L, Toda K, Enokida T, Minami H, Imamura Y, et al: 
Lenvatinib for Anaplastic Thyroid Cancer. Front Oncol 7: 25, 
2017.
21. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, 
Barani L, Marchetti I, Ferrannini E and Miccoli P: Primary cell 
cultures from anaplastic thyroid cancer obtained by fine-needle 
aspiration used for chemosensitivity tests. Clin Endocrinol 69: 
148-152, 2008.
22. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, 
Marchetti I, ugolini C, Basolo F, Miccoli P and Ferrannini E: 
Evaluation of the sensitivity to chemotherapeutics or thiazolidin-
ediones of primary anaplastic thyroid cancer cells obtained by 
fine-needle aspiration. Eur J Endocrinol 159: 283-291, 2008.
23. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, 
Minuto M, Giannini R, Marchetti I, Barani L, Basolo F, et al: 
Thiazolidinediones and antiblastics in primary human anaplastic 
thyroid cancer cells. Clin Endocrinol 70: 946-953, 2009.
24. Fiore L, Pollina LE, Fontanini G, Casalone R, Berlingieri MT, 
Giannini R, Pacini F, Miccoli P, Toniolo A, Fusco A, et al: 
Cytokine production by a new undifferentiated human thyroid 
carcinoma cell line, FB-1. J Clin Endocrinol Metab 82: 
4094-4100, 1997.
25. Agretti P, De Marco G, De Servi M, Marcocci C, Vitti P, 
Pinchera A and Tonacchera M: Evidence for protein and mRNA 
TSHr expression in fibroblasts from patients with thyroid-asso-
ciated ophthalmopathy (TAO) after adipocytic differentiation. 
Eur J Endocrinol 152: 777-784, 2005.
26. Copland JA, Marlow LA, Williams SF, Grebe SK, Gumz ML, 
Maples WJ, Silverman VE and Smallridge RC: Molecular 
diagnosis of a BRAF papillary thyroid carcinoma with multiple 
chromosome abnormalities and rare adrenal and hypothalamic 
metastases. Thyroid 16: 1293-1302, 2006.
27. Christensen L, Blichert-Toft M, Brandt M, Lange M, Sneppen SB, 
Ravnsbaek J, Mollerup CL, Strange L, Jensen F, Kirkegaard J, 
et al: Thyroperoxidase (TPO) immunostaining of the solitary 
cold thyroid nodule. Clin Endocrinol 53: 161-169, 2000.
28. Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Piaggi S, 
Gelmini S, Lupi C, Minuto M, Berti P, Benvenga S, et al: 
Dysregulation of secretion of CXC alpha-chemokine CXCL10 in 
papillary thyroid cancer: Modulation by peroxisome proliferator-
activated receptor-gamma agonists. Endocr Relat Cancer 16: 
1299-1311, 2009.
29. Antonelli A, Bocci G, La Motta C, Ferrari SM, Fallahi P, 
Fioravanti A, Sartini S, Minuto M, Piaggi S, Corti A, et al: Novel 
pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with 
antitumoral activity in vitro and in vivo in papillary dedifferen-
tiated thyroid cancer. J Clin Endocrinol Metab 96: E288-E296, 
2011.
30. Antonelli A, Bocci G, La Motta C, Ferrari SM, Fallahi P, Ruffilli I, 
Di Domenicantonio A, Fioravanti A, Sartini S, Minuto M, 
et al: CLM94, a novel cyclic amide with anti-VEGFR-2 and 
antiangiogenic properties, is active against primary anaplastic 
thyroid cancer in vitro and in vivo. J Clin Endocrinol Metab 97: 
E528-E536, 2012.
31. Bocci G, Fioravanti A, La Motta C, Orlandi P, Canu B, 
Di Desidero T, Mugnaini L, Sartini S, Cosconati S, Frati R, et al: 
Antiproliferative and proapoptotic activity of CLM3, a novel 
multiple tyrosine kinase inhibitor, alone and in combination with 
SN-38 on endothelial and cancer cells. Biochem Pharmacol 81: 
1309-1316, 2011.
32. Antonelli A, Fallahi P, ulisse S, Ferrari SM, Minuto M, 
Saraceno G, Santini F, Mazzi V, D'Armiento M and Miccoli P: 
New targeted therapies for anaplastic thyroid cancer. Anticancer 
Agents Med Chem 12: 87-93, 2012.
33. Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, 
El-Naggar AK and Xing M: Highly prevalent genetic alterations 
in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt 
and mitogen-activated protein kinase pathways in anaplastic 
and follicular thyroid cancers. J Clin Endocrinol Metab 93: 
3106-3116, 2008.
34. Shinohara M, Chung YJ, Saji M and Ringel MD: AKT in thyroid 
tumorigenesis and progression. Endocrinology 148: 942-947, 
2007.
35. Santarpia L, El-Naggar AK, Cote GJ, Myers JN and Sherman SI: 
Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated 
protein kinase pathway mutations in anaplastic thyroid cancer. J 
Clin Endocrinol Metab 93: 278-284, 2008.
36. Di Desidero T, Fioravanti A, Orlandi P, Canu B, Giannini 
R, Borrelli N, Man S, Xu P, Fontanini G, Basolo F, et al: 
Antiproliferative and proapoptotic activity of sunitinib on 
endothelial and anaplastic thyroid cancer cells via inhibition of 
Akt and ERK1/2 phosphorylation and by down-regulation of 
cyclin-D1. J Clin Endocrinol Metab 98: E1465-E1473, 2013.
FERRARI et al:  LENVATINIB IN ANAPLASTIC THYROID CANCER2234
37. Antonelli A, Bocci G, Fallahi P, La Motta C, Ferrari SM, 
Mancusi C, Fioravanti A, Di Desidero T, Sartini S, Corti A, et al: 
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic 
properties, is active against primary anaplastic thyroid cancer in 
vitro and in vivo. J Clin Endocrinol Metab 99: E572-E581, 2014.
38. Klein EA and Assoian RK: Transcriptional regulation of the 
cyclin D1 gene at a glance. J Cell Sci 121: 3853-3857, 2008.
39. Lee JJ, Au AY, Foukakis T, Barbaro M, Kiss N, Clifton-Bligh R, 
Staaf J, Borg A, Delbridge L, Robinson BG, et al: Array-CGH 
identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid 
carcinoma. Endocr Relat Cancer 15: 801-815, 2008.
40. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, 
Bugis S, Filipenko D, Huntsman D and Gilks B: Anaplastic thyroid 
carcinoma: Expression profile of targets for therapy offers new 
insights for disease treatment. Ann Surg Oncol 14: 719-729, 2007.
41. Sarkar S, Mazumdar A, Dash R, Sarkar D, Fisher PB and 
Mandal M: ZD6474, a dual tyrosine kinase inhibitor of EGFR 
and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and 
induces apoptosis in breast cancer cells. Cancer Biol Ther 9: 
592-603, 2010.
42. Ye L, Santarpia L and Gagel RF: The evolving field of tyrosine 
kinase inhibitors in the treatment of endocrine tumors. Endocr 
Rev 31: 578-599, 2010.
43. Blumenthal RD and Goldenberg DM: Methods and goals for 
the use of in vitro and in vivo chemosensitivity testing. Mol 
Biotechnol 35: 185-197, 2007.
44. Antonelli A, Ferri C, Ferrari SM, Sebastiani M, Colaci M, 
Ruffilli I and Fallahi P: New targeted molecular therapies for 
dedifferentiated thyroid cancer. J Oncol 2010: 921682, 2010.
